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Abstract Patients with conventional pacemakers or im-
planted defibrillators are often considered for cardiac
resynchronization therapy (CRT). Our aim was to summarize
the available evidences regarding the clinical benefits of up-
grade procedures. A systematic literature search was per-
formed from studies published between 2006 and 2017 in
order to compare the outcome of CRT upgrade vs. de novo
implantations. Outcome data on all-cause mortality, heart fail-
ure events, New York Heart Association (NYHA) Class, QRS
narrowing and echocardiographic parameters were analysed.
A total of 16 reports were analysed comprising 489,568 CRT
recipients, of whom 468,205 patients underwent de novo and
21,363 upgrade procedures. All-cause mortality was similar
after CRT upgrade compared to de novo implantations (RR
1.19, 95% CI 0.88–1.60, p = 0.27). The risk of heart failure
was also similar in both groups (RR 0.96, 95% CI 0.70–1.32,
p = 0.81). There was no significant difference in clinical
response after CRT upgrade compared to de novo implanta-
tions in terms of improvement in left ventricular ejection frac-
tion (ΔEF de novo − 6.85% vs. upgrade − 9.35%; p = 0.235),
NYHA class (ΔNYHA de novo − 0.74 vs. upgrade − 0.70;
p = 0.737) and QRS narrowing (ΔQRS de novo − 9.6 ms vs.
upgrade − 29.5 ms; p = 0.485). Our systematic review and
meta-analysis of currently available studies reports that CRT
upgrade is associated with similar risk for all-cause mortality
compared to de novo resynchronization therapy. Benefits on
reverse remodelling and functional capacity improved similar-
ly in both groups suggesting that CRT upgrade may be safely
and effectively offered in routine practice. Clinical Trial
Registration: Prospero Database—CRD42016043747
Keywords Heart failure . Cardiac resynchronization therapy .
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LVEF Left ventricular ejection fraction
ICD Implantable cardioverter defibrillator
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RR Risk ratio
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Introduction
Cardiac resynchronization therapy (CRT) has been shown to
improve cardiac function, symptoms and hospitalization and
reduce all-cause mortality in heart failure patients with
prolonged QRS and reduced ejection fraction [1]. Since
chronic right ventricular pacing could be deleterious by in-
creasing the risk of heart failure, all-cause mortality and atrial
fibrillation [2, 3], patients implanted with conventional pace-
maker or implantable cardioverter defibrillator (ICD) systems
are often considered for upgrading to CRT.
Recent studies suggested that patients with typical left bun-
dle branch block (LBBB) ECG morphology derive the most
benefit from CRT [4, 5]. Although right ventricular pacing
could trigger similar ventricular dyssynchrony to LBBB, data
are scarce regarding the benefits of upgrading to CRT in pa-
tients with previously implanted cardiac pacemaker or ICD
systems.
The latest ESC guidelines on cardiac pacing and
resynchronization therapy recommends CRT upgrade as a
class I indication (level B) for symptomatic patients (New
York Heart Association (NYHA) III–IVa) with low ejection
fraction (LVEF ≤ 35%) [6]; however, the most recent
European heart failure guidelines restrict this indication as a
class IIb (level B) [7], due to lack of randomized clinical data
available. In contrast, ACC guidelines focus mostly on the
percentage of right ventricular pacing rather than symptoms
or functional status [8].
While we are awaiting further data of prospective clinical
trials on the effects of CRT upgrade on left ventricular reverse
remodelling and clinical outcomes, we need more data for
routine clinical practice. Therefore, we aimed to provide a
detailed analysis of the available evidence comparing clinical
outcomes and long-term survival between CRT upgrade and
de novo implantations.
Methods
Study selection
This systematic review was performed according to the
PRISMA statement [9], and a predefined review protocol
was published in the PROSPERO database under the registra-
tion number of CRD42016043747 [10]. A comprehensive
search of PubMed, ResearchGate and GoogleScholar data-
bases was performed from January 2006 to March 2017 fo-
cusing on full-sized, peer-reviewed, English language papers
reporting data on patient outcomes after upgrade CRT vs. de
novo implantations as a comparator group. In order to identify
all potentially relevant articles, the search was performed by
using the terms of (1) Bupgrade^ AND BCRT^ and (2)
Bupgrade^ AND Bcardiac resynchronisation therapy .^ The
search was also extended by using the name of the most fre-
quently cited authors of the identified studies. In addition,
references of relevant review articles were also searched to
find appropriate manuscripts.
Potentially relevant articles were evaluated by three inde-
pendent reviewers (A.K., M.V., R.S.), and additional manu-
scripts were retrieved that either reviewer felt were potentially
relevant. According to our review protocol, studies were ac-
cepted for analysis if (i) including heart failure patients with
reduced ejection fraction (HFrEF) with de novo and upgrade
CRT implantations, (ii) reporting all-cause mortality data or
heart failure events and (iii) reporting echocardiographic (i.e.
LVEF, end-diastolic volume (EDV)) or clinical (NYHA class)
or ECG (QRS width) parameters of reverse remodelling
(Supplementary Table 1). Heart failure events were defined
as hospitalization due to progression of heart failure.
Corresponding authors were contacted for unpublished infor-
mation and permission in the case of missing relevant data
sets. In order to evaluate the heterogeneity of patients who
were enrolled into each therapy groups, the most important
baseline clinical characteristics were collected and compared.
Data on procedure-related complications were also collected if
available.
Statistical analysis
All stat is t ical analyses were conducted uti l izing
Comprehensive Meta-Analysis 3.3 (Biostat, Inc., USA) and
GraphPad Prism Software Version 7 (GraphPad Prism Inc.,
San Diego, CA, USA). Heterogeneity between individual trial
estimates was assessed using the Q statistic and I2 statistic
[11]. Since there was significant heterogeneity in the design
and patient characteristics of the included studies, it was as-
sumed that the true effect size varies from one study to the
other, and hence, the random-effect model was used [12]. As a
principal yet conservative measurement of the effect size (i.e.
all-cause mortality), we calculated risk ratios (RRs) along with
a 95% upper and lower confidence interval (CI) and compared
the two therapy groups as case-control models. Additionally,
meta-analysis was performed for publications where crude
and/or adjusted hazard ratios (HRs) were also available.
Sensitivity analysis with the inclusion of prospective studies
only was performed. Forest plots were constructed showing
the individual trials with the pooled estimates. Publication bias
was assessed using the funnel plot, the trim and fill method of
Duval and Tweedie [13] and an adjusted rank correlation test
according to Begg andMazumdar [14]. Since we did not have
access to individual patient data from all studies reviewed, the
median of delta values for LVEF, EDV, NYHA and QRS was
calculated and compared between the two patient groups by
using the Mann-WhitneyU test. Methodological quality of all
studies was assessed using the methodological index for non-
randomized studies (MINORS) [15, 16]. Studies were defined
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to be low, moderate and high-quality studies based on their
MINORS scores of < 8, < 16 and ≥ 16 points (Supplementary
Table 2).
Results
Study characteristics
A total of 16 reports were selected for the current analysis
comprising 489,568 CRT recipients, of whom 468,205 pa-
tients had de novo resynchronization therapy and 21,363 pa-
tients underwent an upgrade procedure (Fig. 1). The charac-
teristics of all included studies are shown in Table 1. None of
the identified studies was a randomized, controlled trial. Most
of them were observational, retrospective [17–28] or observa-
tional prospective [29–32] cohort studies. The vast majority
were single-centre observations [17, 19–21, 23–26, 29, 30]
with the exception of four dual/multicentre studies [18, 22,
28, 32] and two based on high volume registries (European
survey [27] and United States National Database [28]). Four
[26, 29, 31, 32] from the 16 studies proved to be high-quality
reports (average MINORS score 11.4, Supplementary
Table 2).
The most important published patient characteristics of the
included studies, such as age, gender, aetiology, baseline QRS
duration (paced in upgrade, intrinsic in de novo groups), base-
line NYHA functional class, baseline left ventricular ejection
fraction and dimensions are summarized in Supplementary
Table 3. In summary, the mean ejection fraction was by defi-
nition lower than 35% in all studies, and there were no signif-
icant differences between the de novo and upgrade groups in
most of the individual studies. Most of the trials enrolled pa-
tients with severe symptoms (NYHA III–IVa); a smaller ex-
tent of the studies investigated patients without depicting
functional class. More than 50% of the studies found signifi-
cant differences in the following baseline parameters between
the two patient groups: age, atrial fibrillation and QRS dura-
tion. In the upgrade group, patients were generally older, more
likely to have atrial fibrillation and they had wider (paced)
QRS.
All-cause mortality and heart failure events
Crude mortality rates were available in 489,197 patients from
11 studies [17, 19, 21, 22, 24, 26–29, 31, 32], while unadjust-
ed or adjusted hazard ratios were available for 1734 and 1229
patients in 4 [19, 26, 31, 32] and 3 [19, 31, 32] studies, re-
spectively. All-cause mortality did not differ following up-
grade compared to de novo implantations (RR 1.19, 95% CI
0.88 to 1.60, p = 0.27, I2 = 90.1%, Fig. 2). Pooled analyses of
the unadjusted or adjusted hazard ratios revealed similar find-
ings (crude HR 1.07, 95% CI 0.72 to 1.57, p = 0.74,
I2 = 73.6%, Supplementary Fig. 1a) (adjusted HR 0.81, 95%
CI 0.36 to 1.81, p = 0.61, I2 = 88.5%, Supplementary Fig. 1b).
When only prospective studies were analysed, no differ-
ences were found between the two groups (RR 1.10, 95%
CI 0.76 to 1.60, p = 0.60, I2 = 54.0%, Supplementary Fig. 1c).
In studies providing appropriate information, the unadjust-
ed risk of heart failure was also similar in de novo and upgrade
CRT groups (RR 0.96, 95% CI 0.70 to 1.32, p = 0.81,
I2 = 28.0%, Fig. 3).
Left ventricular reverse remodelling, clinical
improvement
The extent of reverse remodelling in terms of improvement in
left ventricular ejection fraction and end-diastolic volume was
similar in the two patient groups (ΔEF de novo − 6.85% vs.
upgrade − 9.35%, p = 0.235; ΔEDV de novo − 23.0 vs.
Table 2 Complications during de novo CRT vs. upgrade CRT implantations
Duray[29] Bogale[27] Horst[24] Cheung[28]
upgrade de novo upgrade de novo upgrade de novo upgrade de novo
Number of patients 18 61 692 1675 134 134 19564 464246
Procedure time 164 ±63 154 ±44 100 (60-140) 100 (70-140) na na na na
X-Ray time (min) 32 ± 22 25 ± 18 15 (8-27) 18 (11-29) na na na na
X-Ray dose (mGy) 52 ± 49 41 ± 31 na na na na na na
Tamponade 0 0 3 (0.4%) 4 (0.3%) 0 2 (1.5%) na na
Perforation 0 0 na na na na 254 (1.3%) 1857 (0.4%)
Vena cava superior dissection 1 (6%) 0 na na 0 1 (0.8%) na na
Coronary Sinus Dissection 1 1 6 (0.9%) 25 (1.5%) 4 (3%) 4 (3%) na na
Pocket haematoma 0 1 26 (4.2%) 46 (3.1%) na na na na
Bleeding / Trasfusion due to 
bleeding
0 1 4 (0.6%) 15 (1.0%) 2 (1.5%) 0
na na
Allergic reaction 0 1 na na na na na na
PTX 0 1 3 (0.5%) 16 (1.1%) 1 (0.8%) 4 (3%) 254 (1.3%) 5107 (1.1%)
Infection 0 0 na na na na na na
Lead revision / dislocation 0 2 (3%) 11 (1.8%) 48 (3.2%) 2 (1.5%) 5 (4%) 657 (2.9%) 7892 (1.7%)
Phrenicus nerve stimulation na na 11 (1.8%) 35 (2.3%) 4 (3%) 10 (8%) na na
Parameters with significant difference in the original reports are highlighted with bold verbatim
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upgrade − 20.0 ml; p = 0.730) (Fig. 4a, b). Regarding symp-
toms, change in NYHA functional class was also comparable
after de novo CRT implantation and upgrade procedures
(ΔNYHA de novo − 0.74 vs. upgrade − 0.70 class;
p = 0.737) (Fig. 5). When QRS narrowing was compared,
no significant difference was found between the two patient
groups (ΔQRS de novo − 9.6 vs. upgrade − 29.5 ms;
p = 0.485) (Fig. 5b).
System-related complications
Based on four studies [24, 27–29], where detailed analyses
regarding system-related complications were published, fluo-
roscopic time [27], the rate of phrenic nerve stimulation [24],
cardiac perforation, pneumothorax and lead dislocation [28]
showed significant difference between the two patient groups
(Table 2). In the largest database [28], the most severe com-
plications such as lead revision, pneumothorax or perforation
were observed more frequently in the upgrade group.
Another prospective, multicentre registry which was de-
signed to demonstrate complication rates in patients with
6 months after pacemaker or ICD replacement has to be men-
tioned; however due to its study design, it was not eligible for
including in the current analyses [33]. In this registry [33], 713
patients were upgraded, and the most frequent major compli-
cation was lead dislodgement or malfunction observed in
7.9% of patients, while 1.5% experienced haematoma and
0.8% infection in the first 6 months after the procedure.
Fig. 1 Flow chart of searching
for publications
Fig. 2 Risk of all-cause mortality
(risk ratio) after de novo vs. up-
grade CRT
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Publication bias
According to the rank correlation test of Begg and Mazumdar,
there was no evidence of significant publication bias (mortality
RR: τ = − 0.236, p = 0.312; mortality RR in prospective trials:
τ = − 0.167, p = 0.734; mortality crude HR: τ = − 0.167,
p = 0.734; mortality adjusted HR: τ = 0.333, p = 0.602; HF
RR: τ = 0, p = 1.000). Furthermore, corresponding to the Duval
and Tweedie’s trim and fill input method, there was no evi-
dence that publication bias would significantly impact on the
overall effect sizes observed (Supplementary Figs. 2–6).
Discussion
Main findings
This systematic review of 16 studies comparing data in ap-
proximately 500,000 patients undergoing de novo or upgrade
CRT implantations revealed no significant difference in all-
cause mortality or heart failure events between the two patient
groups. Also, no significant differences were found in changes
of echocardiographic parameters of reverse remodelling (EF,
EDV). Functional changes (i.e. improvement of NYHA
Fig. 3 Risk of heart failure
events after de novo vs. upgrade
CRT
Fig. 4 a Change in ejection
fraction after de novo vs. upgrade
CRT. b Change in end-diastolic
volume after de novo vs. upgrade
CRT
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functional class) and narrowing of QRS were also similar,
suggesting that adding left ventricular pacing in patients with
prior cardiac devices may be a safe and feasible procedure
with similar clinical benefits as de novo implantations.
Patient population referred to biventricular upgrade
Biventricular upgrade affects roughly 5–10% of patients who
underwent ICD or pacemaker implantation [33, 34]. Due to
the right ventricular (RV) pacing-induced dyssynchrony, pa-
tients with a high percentage of RV pacing are at high risk of
adverse clinical outcomes [2, 3] and could become candidates
for CRT upgrade. Wilkoff et al. demonstrated in the DAVID
trial that the percent of RV pacing correlated with the com-
posite of death or rehospitalizations for HF in ICD recipients
with a high rate of DDD pacing compared to patients with the
VVI 40/min programming [3]. In addition, echocardiographic
and functional parameters (6-min walk test, symptoms) may
worsen even in patients with previously preserved ejection
fraction [35, 36] or mild heart failure [37] after frequent RV
pacing. In the BLOCK-HF [37] trial, patients with atrioven-
tricular (AV) block, mild symptoms (NYHA II–III) and
HFmrEF or HFrEF (EF < 50%, the baseline mean
EF = 45%) received a CRT device and were randomly
assigned to standard right ventricular or biventricular pacing.
The primary endpoint (composite of all-cause mortality, HF
events, or ≥ 15% increase in LVESVindex) occurred in 190 of
342 patients (55.6%) in the RV pacing group, compared to
160 of 349 patients (45.8%) in the CRT group, which first
demonstrated the superiority of biventricular pacing over RV
pacing in pacemaker-dependent patients.
According to these lines of evidences and considerations, it
seems reasonable upgrading to CRT in HF patients with pre-
viously implanted cardiac devices and a high percentage of
right ventricular pacing. On the other hand, upgrade proce-
dures may be associated with higher surgical risk, such as
venous access issues, the risk of damage or extraction of pre-
viously implanted leads, higher infection rates and longer pro-
cedure times [33, 38], that all together may significantly com-
promise the success of LV pacing.
It should be also noted that aetiology or the cause of de-
creased ejection fraction might be different in upgrade vs. de
novo CRT groups. Regarding the aetiology, similar percent-
age of ischemic and non-ischemic heart disease was reported
in most of the included studies; however, the baseline QRS
was wider (paced QRS), and patients were older and had more
often atrial fibrillation in the upgrade group.
Evidence supporting CRT upgrade
The current guideline recommendations are mainly based on
some non-randomized, observational prospective Bupgrade
vs. de novo^ studies, which are included in the current analy-
sis [17, 18, 23, 27, 30]. In addition, small observational retro-
spective [39–45] and cross-over [46–49] trials are also re-
ferred in the ESC guidelines with a low number of patients.
In most of these trials, only soft endpoints, such as NYHA
functional class, 6-min walk test, quality of life or echocardio-
graphic parameters were analysed. Summarizing the most fre-
quently investigated clinical parameters, such as change in
NYHA functional class, decrease in QRS duration, changes
of left ventricular ejection fraction and end-diastolic volume,
no significant differences were observed between the de novo
and upgrade groups in our analysis.
Data regarding long-term mortality were reported only in a
few prior trials [17, 19, 21, 22, 24, 26–29, 31, 32]. The largest
r e po r t f r om t h e s e wa s t h e Eu r op e an Ca r d i a c
Resynchronization Survey [27] from 2011 comprising 1489
de novo and 601 upgrade CRT patients. Total mortality at
1 year was low and similar in both groups (8.6 vs. 7.9%,
p = 0.57). Although this registry showed representative data
about mortality rates with high number of enrolled patients,
there are a huge number of potential confounders that may
have biased the overall results. Therefore, trials with adjusted
analyses are essential to control baseline differences to better
assess the effects of CRTupgrade on long-term survival. In the
current meta-analysis, three observational studies with adjust-
ed all-cause mortality endpoints were included. Tayal et al.
Fig. 5 a Change in NYHA functional class after de novo vs. upgrade
CRT. b Change in QRS duration after de novo vs. upgrade CRT
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compared 85 patients who underwent de novo CRT implanta-
tion and 50 patients with CRTupgrade [31]. During the 4 years
of follow-up time, patients with prior right ventricular pacing
had a significantly lower risk of fatal events than patients with
de novo CRT implantation (adjusted HR 0.25, 95% CI 0.07–
0.88, P = 0.03). Gage et al. compared 190 patients with prior
high percentage of right ventricular pacing (> 40%) to 465
non-paced patients who underwent CRT implantation [19].
During the median follow-up of 4.2 years, upgrade patients
tended to have better outcomes in terms of all-cause mortality
(adjusted HR 0.73; 95% CI 0.53–1.01; p = 0.055). In contrast,
Vamos et al. recently reported a higher risk for mortality in the
upgrade group when compared to de novo implantation in 552
patients [32]. In this multicentre study with a mean follow-up
of 37 months, patients who underwent CRT upgrade had a
significantly higher risk of all-cause mortality compared to
patients with de novo implantations even after adjusting for
potential confounders with multivariate Cox regression anal-
ysis (adjusted HR 1.68, 95% CI 1.20–2.34, p = 0.002) and
after applying propensity score matching (PS-adjusted HR
1.79, 95% CI 1.08–2.95, p = 0.023). Summarizing all these
results in our meta-analysis, a similar long-term survival was
found between the two patient groups. However, heterogene-
ities in the results of adjusted studies largely emphasize that
randomized controlled trials are needed to objectively clarify
this clinical dilemma.
Besides the aforementioned publications until 2016, there
is another manuscript released in 2017 which has to be
discussed more in details. Cheung et al. recently published a
unique data using the US National Database between 2003
and 2013 including 19,546 patients who underwent CRT up-
grade vs. 464,246 patients after de novo CRT implantations
[28], which was also included in the current analysis. This
study found that patients with de novo CRT implantation were
older, had more frequent third-degree AV block, LBBB or
other comorbidities such as renal failure or ischemic heart
disease. The rate of in-hospital mortality of patients undergo-
ing CRT upgrade was significantly higher than in the de novo
group (1.9 vs. 0.8%; p < 0.001). Regarding complications,
significantly higher rate of pneumothorax, lead revision or
perforation were observed in the upgrade group. These results
are somewhat different from other trials included in our meta-
analysis, where patients undergoing CRT upgrade were gen-
erally older and had more frequent atrial fibrillation. Despite
potential differences in the lengths of follow-up and baseline
patient characteristics, other studies did not reveal a higher
risk for mortality, such as the twofold higher risk in the US
cohort. This pronounced in-hospital mortality rate might be
derived from a de-identified, code-based selection of their
database which may not have been representative for the total
patient cohort dedicated for CRT upgrade.
Despite the current detailed review and meta-analysis of
the available clinical evidence, several questions remain
unanswered. Most striking from these include which popula-
tions may derive the largest benefits from upgrading and what
is the optimal timing for such procedures.
The ongoing BUDAPEST-CRT Upgrade study
(NCT02270840) was designed to evaluate the efficacy and
safety of CRT upgrade from conventional PM or ICD systems
[50]. In this prospective, randomized, multicentre clinical trial
symptomatic heart failure patients (NYHA II–IVa) with low
ejection fraction (EF ≤ 35%), intermittent (≥ 20%) or perma-
nent right ventricular pacing and wide paced QRS (≥ 150 ms)
are randomized to CRT-D or ICD. Based on the primary com-
posite endpoint of all-cause mortality, heart failure events and
less than 15% end-systolic volume reduction at 12-month fol-
low-up, we will obtain more definite data on the risks and
benefits of CRT upgrade procedures.
Limitations
This meta-analysis shows all potential limitations of such a
kind of analysis. Patients in the two groups were not randomly
allocated; all included studies were either retrospective studies
with historical controls or prospective observational data col-
lections; thus, a residual selection bias could not be excluded.
There are remaining clinical issues that have obviously affect-
ed the decision-making on upgrading but could not be collect-
ed and analysed in a systematic fashion, such as the possibility
to avoid RV stimulation by programming appropriately, the
patency of the venous system, need for generator or lead re-
placement due to battery or lead issues and end-stage renal
disease on dialysis or other severe comorbidities including
age. Second, the comparison of these two groups is partly
confusing, while the aetiology of dyssynchrony may be dif-
ferent. In recipients of Bde novo^ CRT, other underlying car-
diac pathophysiological conditions in addition to the initial
dyssynchrony may be present, whereas in the upgrade group,
patients were initially implanted with a pacemaker for a bra-
dycardia indication. Third, we did not have access to individ-
ual patient-level data precluding us from calculating adjusted
hazard ratios for all the included studies. Finally, the length of
follow-up was also heterogeneous in the included reports.
However, so far, this is the largest available comprehensive
evidence in this respect, and sensitivity analysis from adjusted
results corroborated our initial findings.
Conclusions
Our systematic review and meta-analysis of currently avail-
able studies reports that CRT upgrade is associated with sim-
ilar risk for all-cause mortality compared to de novo
resynchronization therapy. Benefits on reverse remodelling
and functional capacity improved similarly in both groups
Heart Fail Rev (2018) 23:15–26 23
suggesting that CRT upgrade may be safely and effectively
offered in routine practice. These results should be confirmed
in further randomized clinical trials.
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